Adherence to antihypertensive medications for secondary prevention of cardiovascular disease events: a dose-response meta-analysis. (July 2021)
- Record Type:
- Journal Article
- Title:
- Adherence to antihypertensive medications for secondary prevention of cardiovascular disease events: a dose-response meta-analysis. (July 2021)
- Main Title:
- Adherence to antihypertensive medications for secondary prevention of cardiovascular disease events: a dose-response meta-analysis
- Authors:
- Feng, Y.
Han, M.
Qie, R.
Huang, S.
Li, Q.
Guo, C.
Tian, G.
Zhao, Y.
Yang, X.
Li, Y.
Wu, X.
Zhou, Q.
Zhang, Y.
Wu, Y.
Liu, D.
Hu, F.
Zhang, M.
Yang, Y.
Shi, X.
Sun, L.
Hu, D. - Abstract:
- Abstract: Objectives: The aim of the study was to explore the association between adherence to antihypertensive medications (AHMs) and the risk of recurrence of cardiovascular disease (CVD) events in patients with a history of CVD events from cohort studies. Study design: This is a dose-response meta-analysis. Methods: PubMed and Embase databases were searched up to March 4, 2021, to identify English-language reports of cohort studies that assessed the association of AHM adherence with risk of recurrence of CVD events. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were estimated by using a fixed- or random-effects model. Restricted cubic splines were used to evaluate the possible linear or non-linear association. Results: We included nine cohort studies (54, 349 patients) in the present meta-analysis. The pooled RR of CVD events was 0.66 (95% CI, 0.54–0.78) for the highest versus lowest AHM adherence category. We did not find any evidence of non-linearity association between AHM adherence and risk of CVD events ( P non-linearity = 0.534); for patients with a history of CVD events, the risk of CVD events was reduced by 9% for each 20% increase in AHM adherence (RR, 0.91; 95% CI, 0.85–0.97). The results of sensitivity analysis and subgroup analysis were virtually unchanged. Conclusions: The high level of adherence to AHM is an effective strategy for preventing recurrence of CVD events. Patients with a history of CVD events should adhere to AHM.
- Is Part Of:
- Public health. Volume 196(2021)
- Journal:
- Public health
- Issue:
- Volume 196(2021)
- Issue Display:
- Volume 196, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 196
- Issue:
- 2021
- Issue Sort Value:
- 2021-0196-2021-0000
- Page Start:
- 179
- Page End:
- 185
- Publication Date:
- 2021-07
- Subjects:
- Antihypertensive medication -- Adherence -- Cardiovascular disease -- Cohort studies -- Meta-analysis
Public health -- Periodicals
Public health -- Periodicals
Electronic journals
362.1 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00333506 ↗
http://intl.elsevierhealth.com/journals/pubh/ ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00333506 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/00333506 ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/public-health ↗ - DOI:
- 10.1016/j.puhe.2021.05.015 ↗
- Languages:
- English
- ISSNs:
- 0033-3506
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6963.850000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18389.xml